As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.
Frequently asked questions
What sector does Kalvista Pharmaceuticals Inc (KALV) operate in?
Kalvista Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Kalvista Pharmaceuticals Inc (KALV) current stock price?
As of the latest data, Kalvista Pharmaceuticals Inc stock price is $27.00, with a previous close of $27.00.
What is Kalvista Pharmaceuticals Inc (KALV) current market capitalization?
Kalvista Pharmaceuticals Inc market cap is approximately 1.44 billion.
What is Kalvista Pharmaceuticals Inc (KALV) Earnings Per Share (EPS)?
The trailing EPS is -$3.94, and the forward EPS is -$2.79.
What is Kalvista Pharmaceuticals Inc (KALV) EBITDA?
Kalvista Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.24 million.
Does Kalvista Pharmaceuticals Inc (KALV) pay dividends?
No. Kalvista Pharmaceuticals Inc does not pay a dividend.
When is Kalvista Pharmaceuticals Inc (KALV) next earnings report?
Kalvista Pharmaceuticals Inc is expected to release its next earnings report on July 31, 2026.
What is Kalvista Pharmaceuticals Inc (KALV) beta (volatility) score?
Kalvista Pharmaceuticals Inc has a beta of -0.109, indicating lower volatility than the overall market.
